Hexobendine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585308

CAS#: 54-03-5 (free base)

Description: Hexobendine is a potent vasoactive agent that dilates cerebral and coronary arteries, but slightly constricts femoral arteries, without any effects on heart rate, blood pressure or cardiac output.

Chemical Structure

img
Hexobendine
CAS# 54-03-5 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 585308
Name: Hexobendine
CAS#: 54-03-5 (free base)
Chemical Formula: C30H40N2O10
Exact Mass: 588.27
Molecular Weight: 588.654
Elemental Analysis: C, 61.21; H, 6.85; N, 4.76; O, 27.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 54-03-5 (free base)   50-62-4 (dihydrochloride)  

Synonym: Hexobendine; ST 7090; ST7090; ST-7090; Ditrimin; Ditrimine; Ustimon

IUPAC/Chemical Name: Benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediylbis((methylimino)-3,1-propanediyl) ester

InChi Key: GIROHAYVVNQZLT-RYJWMXFHSA-N

InChi Code: InChI=1S/C30H40N2O10/c1-31-21(11-13-41-29(33)19-15-23(35-3)27(39-7)24(16-19)36-4)9-10-22(32-2)12-14-42-30(34)20-17-25(37-5)28(40-8)26(18-20)38-6/h15-18H,9-14H2,1-8H3/b31-21-,32-22-

SMILES Code: C/N=C(CC/C(CCOC(C1=CC(OC)=C(OC)C(OC)=C1)=O)=N/C)\CCOC(C2=CC(OC)=C(OC)C(OC)=C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 588.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kolassa N, Dŏrr B, Pfleger K. [Studies on the pharmacokinetics of hexobendine in rats. I. Distribution following i.v. administration (author's transl)]. Arzneimittelforschung. 1975 Sep;25(9):1414-7. German. PubMed PMID: 1242664.

2: Kolassa N, Stengg R, Turnheim K. Influence of hexobendine, dipyridamole, dilazep, lidoflazine, inosine and purine riboside on adenosine uptake by the isolated epithelium of guinea pig jejunum. Pharmacology. 1978;16(1):54-60. PubMed PMID: 619363.

3: McInnes L, Parratt JR. Studies on the mode of action of hexobendine, a prospective anti-anginal drug. Br J Pharmacol. 1969 Sep;37(1):272-82. PubMed PMID: 5343351; PubMed Central PMCID: PMC1703777.

4: Plagemann PG, Kraupp M. Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine. Biochem Pharmacol. 1986 Aug 1;35(15):2559-67. PubMed PMID: 3741459.

5: Shibata K, Hayashi S, Toda N. [Influence of hexobendine, prenylamine and verapamil on the contractile response of isolated rabbit left atria and aortae to calcium (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Nov;73(8):931-8. Japanese. PubMed PMID: 611068.

6: Winkler R, Moser M. [Effect of hexobendine and pentoxifylline on the viscosity of erythrocyte suspension]. Wien Klin Wochenschr. 1983 Mar 18;95(6):209-13. German. PubMed PMID: 6880203.

7: Iwata H, Masukawa T, Kakuno K, Yamamoto I. [Effects of hexobendine on adenosine metabolism and myocardial energy metabolism (author's transl)]. Nihon Yakurigaku Zasshi. 1978 Oct;74(7):833-40. Japanese. PubMed PMID: 744550.

8: Rothaul AL, Broadley KJ. Use of hexobendine to examine whether the coronary vasodilator metabolite released from guinea-pig isolated hearts is adenosine. Cardiovasc Res. 1981 Oct;15(10):599-610. PubMed PMID: 7317912.

9: Diene G, Nigro P, Cottini E, Andreozzi GM, Mossuti E, Sorrentino F. [Recent contribution to the study on the effects of hexobendine in the treatment of coronary insufficiency]. Boll Soc Ital Cardiol. 1973;18(12):1213-21. Italian. PubMed PMID: 4619973.

10: Kolassa N, Pfleger K, Träm M. Species differences in action and elimination of adenosine after dipyridamole and hexobendine. Eur J Pharmacol. 1971;13(3):320-5. PubMed PMID: 5577493.

11: Kolassa N, Dörr B, Pfleger K. [Studies on the pharmacokinetics of hexobendine in rats / 2nd communication: Elimination following i.v. administration (author's transl)]. Arzneimittelforschung. 1975 Oct;25(10):1567-70. German. PubMed PMID: 1243039.

12: Hulme ME, Weston AH. Some effects of dipyridamole, hexobendine and lidoflazine on inhibitory processes in rabbit duodenum. Br J Pharmacol. 1974 Apr;50(4):609-11. PubMed PMID: 4447864; PubMed Central PMCID: PMC1776734.

13: Satchell DG, Lynch A, Bourke PM, Burnstock G. Potentiation of the effects of exogenously applied ATP and purinergic nerve stimulation on the guinea-pig taenia coli by dipyridamole and hexobendine. Eur J Pharmacol. 1972 Sep;19(3):343-50. PubMed PMID: 4344978.

14: Balcar VJ, Gundlach AL, Johnston GA. High affinity uptake of cAMP in rat brain: Inhibition by coronary vasodilators dilazep and hexobendine. Neurochem Int. 1988;12(1):19-24. PubMed PMID: 20501198.

15: Klebel VE. [Experimental psychological study of the effect of a hexobendine-etamivan-etofylline combination]. Arzneimittelforschung. 1975 May;25(5):831-6. German. PubMed PMID: 1242334.

16: Kraupp O, Niessner H, Ploszczanski B, Adler-Kastner L, Springer A, Chirikdjian JJ. A comparison of the effects of hexobendine with those of anoxia on the concentration of myocardial metabolites in vivo. Eur J Pharmacol. 1967 Mar;1(2):140-52. PubMed PMID: 6060192.

17: McHenry LC Jr, Jaffe ME, Kawamura J, Goldberg HI. The effect of Hexobendine on regional cerebral blood flow in stroke patients. Neurology. 1970 Apr;20(4):375. PubMed PMID: 5534978.

18: Zimmermann W. [Clinical experience with N,N'-dimethyl-N,N'-bis-(3-(3',4',5'-trimethoxybenzoyloxy)-propyl)-ethylenediamine dihydrochloride (hexobendine)]. Arzneimittelforschung. 1968 Aug;18(8):1112-4. German. PubMed PMID: 5756048.

19: Turnheim K, Plank B, Kolassa N. Inhibition of adenosine uptake in human erythrocytes by adenosine-5'-carboxamides, xylosyladenine, dipyridamole, hexobendine, and p-nitrobenzylthioguanosine. Biochem Pharmacol. 1978;27(18):2191-7. PubMed PMID: 728171.

20: Cook P, James I. Drug therapy: cerebral vasodilators (first of two parts). N Engl J Med. 1981 Dec 17;305(25):1508-13. Review. PubMed PMID: 7029283.